Podcasts about Basic research

In this episode, Logan is joined by Zach Weinberg (Co-Founder/CEO @ Curie.Bio) and Derek Thompson (writer at The Atlantic) for a candid discussion on the state of U.S. healthcare and scientific progress. They unpack what went right, and wrong, with COVID vaccine policy, the public backlash against mRNA technology, and the ripple effects on trust in science. The conversation also dives into the real reasons behind NIH budget cuts, the economics of drug discovery, and the business incentives in medical R&D. It's a sharp, thought-provoking look at the intersection of policy, innovation, and public perception. (00:00) Introduction to Drug Pricing in the US (00:23) Broad Healthcare Topics and Open-Ended Discussion (02:37) COVID-19 Vaccines: Successes and Public Perception (06:21) The Evolution of COVID-19 and Vaccine Efficacy (07:59) Public Policy and Vaccine Mandates (13:10) Impact of School Closures and Public Sentiment (19:23) NIH Funding and the Importance of Basic Research (25:04) Challenges in Science Funding and Public Perception (35:19) Government vs. Private Investment in Science (36:40) Operation Warp Speed: A Case Study (39:07) Antibiotic Resistance Crisis (43:22) The Drug Pricing Debate (44:05) Challenges in Drug Discovery (54:06) Regulatory Hurdles in Medical R&D (58:06) The Future of Drug Development (01:04:19) Concluding Thoughts Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

In conflict settings, ensuring that social protection is responsive, durable, and conflict-sensitive is critical, yet often underexplored. In this episode, we delve into the intersections between humanitarian assistance, development cooperation, and peacebuilding – the so-called "Triple Nexus" – and how social protection fits within it. We examine how social protection actors, humanitarian agencies and peacebuilding specialists can work together to strengthen resilience, foster stability, and avoid exacerbating conflict. Our guests explore lessons from contexts like Ethiopia and Ukraine, the complexities of targeting and accountability, and the political dimensions of social protection in fragile and conflict-affected settings. This marks the third and final episode of the "Social Protection in Conflict and Protracted Crisis" series, produced by socialprotection.org, organised by STAAR Facility and BASIC Research and in partnership with the Foreign, Commonwealth and Development Office, FCDO, which has funded the series and provided invaluable support in shaping the episodes and connecting us with guests. Meet our guests: Ric Goodman – Director, Social Protection and Resilience, DAI Global UK Rachel Goldwyn – Senior Conflict Sensitivity and Social Safeguards Advisor, WFP Sudan Lukáš Voborský – Team Leader, Technical Assistance Facility of the PeReHID Initiative For our Quick Wins segment, we welcome Hassan-Alattar Satti, independent researcher and consultant, who shares key resources on maintaining social protection in conflict settings, focusing on lessons from Sudan. Resources: Publication | Maintaining and strengthening social assistance systems in conflict settings: Sudan case study Publication | Effective Social Protection in Conflict: Findings from Sudan Blog | Towards a conflict-sensitive role for grassroot organisations in social protection in Sudan

Like many organizations, the Information Technology and Innovation Foundation urges the Trump administration to maintain funding for basic research. Its Center for Life Sciences Innovation cites research showing that federal funding has catalyzed most of the transformative drugs developed in the U.S. More now from center's associate director, Sandra Babosu. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Like many organizations, the Information Technology and Innovation Foundation urges the Trump administration to maintain funding for basic research. Its Center for Life Sciences Innovation cites research showing that federal funding has catalyzed most of the transformative drugs developed in the U.S. More now from center's associate director, Sandra Babosu. Learn more about your ad choices. Visit podcastchoices.com/adchoices

I dette afsnit dykker vi ned i den fascinerende forbindelse mellem videnskab, forskning og teknologisk udvikling. Vores Fokus er det kontroversielle "Project Hindsight" – en omfattende undersøgelse lanceret efter 2. verdenskrig. Projektet havde til formål at kortlægge, hvordan ressourcer blev fordelt mellem teknologiudvikling og grundforskning. Resultaterne viste sig at være yderst kontroversielle og satte gang i en vedvarende debat blandt forskere og ingeniører: Hvor stor en rolle spiller grundforskning egentlig i udviklingen af ny teknologi? Lyt med, når vi udforsker de spændende perspektiver og diskuterer, hvordan fortidens prioriteringer stadig påvirker os i dag.Kilder: Project hindsight. A Defense Department study of the utility of researchhttps://pubmed.ncbi.nlm.nih.gov/6025113/What's Special about Basic Research?https://sciencepolicy.colorado.edu/students/envs_5100/calvert_2006_2.pdfHvis du vil være med til at optage live med os på Discord kan dustøtte os på 10er og blive en af vores kernelyttere https://vudfordret.10er.app Du kan også tjekke vores webshop: bit.ly/vushop. Der er enhønsetrøje! Send os vanvittig videnskab eller stil et spørgsmål på facebook,Instagram eller vudfordret@gmail.com Tak til Christian Eiming for disclaimer.Tak til Barometer-Bjarke for Gak-O-meteret. Husk at være dumme

Featuring articles on pembrolizumab perioperative therapy in breast cancer, reduced dose schedules or fractional doses of pneumococcal conjugate vaccine, and nivolumab plus ipilimumab in colorectal cancer; a review article on degenerative rotator-cuff disorders; a case report of a man with seizures and agitation; a Clinical Implications of Basic Research on boning up on boning up; and Perspectives on the Duffy null phenotype; on sickle cell trait, inequity, and the need for change, on “target trial emulation” for observational studies, and on a good day.

The symptoms of irritability associated with autism spectrum disorder (ASD) include aggression, tantrums, self-injury, and disruption. Propranolol, a beta-blocker, has accumulated much anecdotal evidence as a promising option for symptoms of these disorders, but well-designed studies are rare. Dr. Eric London is the lead author of the article “High-dose propranolol for severe and chronic aggression in autism spectrum disorder: A pilot, double-blind, placebo-controlled, randomized crossover study,” which is published in the September-October 2024 issue of the Journal of Clinical Psychopharmacology. The article describes its effectiveness in decreasing aggression in individuals with ASD. As this was a small study, a larger clinical trial is needed. Dr. London is director of Autism Treatment Research at the New York State Institute for Basic Research. In this podcast, he offers extensive background on treatment challenges and the difficult core symptoms of ASD.

Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In particular, research in the field has been limited by a lack of reliable, quantitative tests for monitoring autophagy-lysosome activity. In this interview, Dr. Zhenyu Yue describes his research investigating the cellular and molecular mechanisms for Parkinson's disease and other neurodegenerative diseases, focusing on their work examining the regulation of the autophagy-lysosomal pathway, potential therapeutic targets, and MJFF-funded research that aims to develop sensitive, robust autophagy-lysosome assays to facilitate the discovery of biomarkers for PD using stem cell-derived neurons and biofluids. Zhenyu is the Aidekman Research Professor in the Department of Neurology and Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai. He is also the Director of the Center of Parkinson's Disease Neurobiology and Director of Basic Research of Movement Disorders at Mount Sinai.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In particular, research in the field has been limited by a lack of reliable, quantitative tests for monitoring autophagy-lysosome activity. In this interview, Dr. Zhenyu Yue describes his research investigating the cellular and molecular mechanisms for Parkinson's disease and other neurodegenerative diseases, focusing on their work examining the regulation of the autophagy-lysosomal pathway, potential therapeutic targets, and MJFF-funded research that aims to develop sensitive, robust autophagy-lysosome assays to facilitate the discovery of biomarkers for PD using stem cell-derived neurons and biofluids. Zhenyu is the Aidekman Research Professor in the Department of Neurology and Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai. He is also the Director of the Center of Parkinson's Disease Neurobiology and Director of Basic Research of Movement Disorders at Mount Sinai.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Константин Скрипник окончил философский факультет Ростовского университета, аспирантуру МГУ. Работал сначала на своем философском факультете почти 20 лет, потом был заместителем начальника и начальником филиала Таможенной академии, снова вернулся в университет, где и работает сейчас на кафедре истории философии. По первой специализации логик, сейчас в круге научных интересов история аналитической философии, история семиотики, метафилософия и методология истории философии. Выигрывал конкурсы грантов Российского гуманитарного научного фонда, Российского фонда фундаментальных исследований, Российского научного фонда. Доктор философских наук, профессор, заслуженный работник высшей школы Российской Федерации. Считает, что преподавательская работа, к которой относится с большим пиететом, одна из самых лучших - тем более, что работал на разных иных работах, может сравнить. Кажется, вполне приличный преподаватель. Konstantin Skripnik graduated from the Faculty of Philosophy at Rostov University and completed his postgraduate studies at Moscow State University. He initially worked at his philosophy faculty for almost 20 years, then served as Deputy Head and Head of a branch of the Customs Academy, and later returned to the university, where he currently works in the Department of History of Philosophy. Originally specializing in logic, his current research interests include the history of analytic philosophy, the history of semiotics, metaphilosophy, and the methodology of the history of philosophy. He has won grant competitions from the Russian Humanitarian Science Foundation, the Russian Foundation for Basic Research, and the Russian Science Foundation. He holds a Doctor of Philosophy degree, is a professor, and has been recognized as an Honored Worker of Higher Education of the Russian Federation. He believes that teaching, to which he is deeply dedicated, is one of the best professions - especially since he has worked in various other fields and can make comparisons. He appears to be a quite respectable teacher. ================================SUPPORT & CONNECT:Support on Patreon: ⁠https://www.patreon.com/denofrich⁠Twitter: ⁠https://twitter.com/denofrich⁠Facebook: ⁠https://www.facebook.com/mark.develman/⁠YouTube: ⁠https://www.youtube.com/denofrich⁠Instagram: ⁠https://www.instagram.com/den_of_rich/⁠Hashtag: #denofrichType of unconscious: 3© Copyright 2024 Den of Rich. All rights reserved.

Folge ansehen oder anhören auf YouTube I Apple Podcasts I SpotifyDanke an die WerbepartnerProdotti Amano - Gesichtspflege aus 9 hochwertigen Bio-Ölen - ohne jegliche Zusatzstoffe. Das geniale Bio-Gesichtsöl findest du auf prodottiamano.com.Mit dem Code JULIA10 bekommst du 10% Rabatt auf die Bestellung deines Bio-Gesichtsöls.http://www.prodottiamano.com Kapitel00:00 Das erwartet dich in der Folge02:19 Prododtti Amano - Bio Gesichtsöl aus Oliven04:27 Begrüßung und Ally erzählt über seine Herausforderungen mit Angsttörungen, Depressionen und ADHS08:16 Über seinen Professor findet er zur ketogenen Ernährung10:59 Das Problem der modernen Medizin - wir denken in Silos19:06 Allys erste Schritte in die ketogene Diät - Fehler und was er gelernt hat24:11 Milch und Milchprodukte36:25 Ketone messen, Fasten und ausreichende Versorgung mit Mikronährstoffen40:49 KetoFeel Studie - was wird gemacht und wie läuft sie abWir sprechen überWir sprechen über Allys' persönliche Reise und seine wichtigen Erkenntnisse.Die Geburtsstunde einer komplett neuen Fachrichtung: Metabolic Psychiatriy und den Aktuellen Wissensstand und die Zukunft der ketogenic metabolic therapy für psychiatrische Erkrankungen.Individualisierung ist zentral: Es ist wichtig, die individuellen Bedürfnisse und Reaktionen des Körpers bei der Anpassung der ketogenen Diät zu berücksichtigen. Nahrungsmittelunverträglichkeiten und -allergien können eine Rolle bei mentalen Gesundheitsproblemen spielen.Milchprodukte -   ja oder nein?  Die KetoFeel Studie - Ally erklärt worum es in der Studie gehen wird und wie sie aufgebaut sein wird.  https://www.gofundme.com/f/ketofeel-oxford-studyAlles über Ally Houstonhttps://metpsy.com/Ally war in seinem “früheren” Leben Physiker. Nachdem er unter ADHS, saisonaler Depression, chronischer Angst und einer Reihe anderer metabolischer Probleme gelitten hatte, führte eine paläo-ketogene Diät und Lebensstiländerungen zu einem Quantensprung in seiner Gesundheit. Der Effekt war so tiefgreifend, dass er den Beruf wechselte. Er ist jetzt metabolic mental health Coach, ausgebildet von PreKure und Dr. Georgia Ede. Im Jahr 2025 wird er an der Universität Oxford eine Studie leiten, die die ketogene Diät plus MetPsy für ADHS mit Depression testet.https://baszuckigroup.com/https://www.metabolicmind.org/Relevante ArtikelDr. Georgia Ede https://www.diagnosisdiet.com/Calabrese, Lori, Rachel Frase, and Mariam Ghaloo. "Complete remission of depression and anxiety using a ketogenic diet: case series." Frontiers in Nutrition 11 (2024): 1396685. https://www.frontiersin.org/articles/10.3389/fnut.2024.1396685/fullCampbell, Iain H., et al. "A Pilot Study of a Ketogenic Diet in Bipolar Disorder: Clinical, Metabolomic and Magnetic Resonance Spectroscopy Outcomes." medRxiv (2023): 2023-10. https://www.medrxiv.org/content/10.1101/2023.05.28.23290595v1Dietch, D.M. et al. (2023) ‘Efficacy of low carbohydrate and ketogenic diets in treating mood and anxiety disorders: systematic review and implications for clinical practice', BJPsych Open, 9(3), p. e70. Available at: https://doi.org/10.1192/bjo.2023.36.Danan, A. et al. (2022) ‘The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients', Frontiers in Psychiatry, 13, p. 951376. Available at: https://doi.org/10.3389/fpsyt.2022.951376.Omori, N.E. et al. (2023) ‘Exploring the role of ketone bodies in the diagnosis and treatment of psychiatric disorders', Frontiers in Psychiatry, 14, p. 1142682. Available at: https://doi.org/10.3389/fpsyt.2023.1142682.Sethi S, Ford JM. The Role of Ketogenic Metabolic Therapy on the Brain in Serious Mental Illness: A Review. Journal of Psychiatry and Brain Science. 2022;7(5). doi:10.20900/jpbs.20220009Mentzelou, M. et al. (2023) ‘The Relationship of Ketogenic Diet with Neurodegenerative and Psychiatric Diseases: A Scoping Review from Basic Research to Clinical Practice', Nutrients, 15(10), p. 2270. Available at: https://doi.org/10.3390/nu15102270.Tillery EE, Ellis KD, Threatt TB, Reyes HA, Plummer CS, Barney LR. The use of the ketogenic diet in the treatment of psychiatric disorders. Mental Health Clinician. 2021;11(3):211-219. doi:10.9740/mhc.2021.05.211BuchtippsChange Your Diet, Change Your Mind: A powerful plan to improve mood, overcome anxiety and protect memory for a lifetime of optimal mental health by Dr. Georgia Edehttps://amzn.to/4bZIpRNBrain Energy: A Revolutionary Breakthrough in Understanding Mental Health--and Improving Treatment for Anxiety, Depression, OCD, PTSD, and More by Chris Palmer, MDhttps://amzn.to/45ukJlKDanke an die Werbepartner, ohne deren Unterstützung dieser Podcast nicht möglich wäre.Prodotti Amano - Gesichtspflege aus 9 hochwertigen Bio-Ölen - ohne jegliche Zusatzstoffe. Prodotti Amano ist ein kleines, feines Startup, das nicht nur Labor-zertifiziertes TOP Extra Vergine Bio-Olivenöl produziert, nein – sie haben jetzt auch ein wirklich einzigartiges Bio-Gesichtsöl entwickelt.Neben Olivenöl aus eigenem regenerativem Anbau, sind unter anderem kostbare Öle wie BIO-Kaktusfeigenkernöl, BIO-Granatapfelkernöl, BIO-Traubenkernöl und BIO- Sanddornfruchtfleischöl enthalten.Das geniale Bio-Gesichtsöl findest du auf prodottiamano.com.Mit dem Code JULIA10 bekommst du 10% Rabatt auf die Bestellung deines Bio-Gesichtsöls.http://www.prodottiamano.com Zeige deinen SupportDir gefällt die Show und die Inhalte? Der beste Weg, uns zu unterstützen, kostet dich nur ein paar Sekunden. Hinterlasse eine Bewertung und/ oder einen Kommentar auf YouTube, iTunes oder Spotify. Bevor wir beginnen, möchte ich mich bei meinen Sponsoren bedanken, deren Unterstützung es mir ermöglicht, regelmäßig spannende Inhalte für dich zu erarbeiten. Bitte beachten Sie auch immer den aktuellen "Haftungsausschluss (Disclaimer) und allgemeiner Hinweis zu medizinischen Themen" auf https://juliatulipan.com/haftungsausschluss/

Before the 1990s, small bits of RNA were considered junk by most, but the 1993 discovery of microRNA (miRNAs) began to reveal that bits of only 19-24 nucleotides of RNA can have an important gene regulation function in cells. Since their discovery, there has been a flurry of work to catalog known miRNAs and understand their functions, which include being tied to specific disease states such as leukemia. According to our guest, Dr. Guy Novotny, Molecular Biologist at Herlev Hospital in Copenhagen, it's now relatively easy to identify a miRNAs and follow their expression, but to figure out what they're actually doing is a real challenge. We hear how he and his team have recently adopted digital PCR, and the benefits that come with it, to study microRNAs and figure out what proteins they're regulating the expression of. This includes basic research, where Guy is “adding to the big pile of data that's existing out there,” and he also does clinical research that has a closer connection to specific disease states and subject outcomes. As always, you'll get to learn about his career journey and learn that there's really not much that cake cannot fix.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Dr. Anat Lea Bonshtien ist die ehemalige Direktorin der Smart Mobility Initiative in Israel und heute Partnerin bei Mobilion Ventures. Im Mobility Pioneers Podcast spricht sie mit Björn Bender  unter anderem über> den Aufbau der Smart Mobility Initiative> die Kollaboration diverser Stakeholder im Ökosystem> die Herausforderung des nächsten grossen Wandels: Der Änderung von MobilitätsverhaltenAnat Lea Bonshtien: https://www.linkedin.com/in/anat-lea-bonshtien/Björn Bender: https://www.linkedin.com/in/benderbjoern/IMO-HSG: IMO-HSG: imo.unisg.chDie Episode wurde am 15. September 2023 aufgezeichnet. 

This week we sit down with Catherine Cabral-Marotta as she shares her journey to becoming an Osteopathic Manual Practitioner and the exciting launch of Ontario's first Honours Bachelor of Science – Osteopathy program.   ABOUT CATHERINE, BSC HK, BSc Ost, Dip SIM, Dip MT Osteopathic Manual Practitioner, Certified Athletic Therapist, Registered Massage Therapist, Certified Strength & Conditioning Specialist In 2004 Catherine graduated with honours from the University of Guelph and Sheridan College where she earned concurrent degrees, an Honours Bachelor of Science degree in Human Kinetics, and an Honours Bachelor of Applied Health Sciences - Athletic Therapy. After passing the national board exams to become a Certified Athletic Therapist, Catherine went on to become certified as a Strength & Conditioning Specialist with the National Strength & Conditioning Association, and a certified Athletic Trainer with the National Athletic Trainers Association Board of Certification in the USA. To complement her advanced manual therapy techniques, Catherine became qualified as a Registered Massage Therapist in August 2011. In November 2011 Catherine successfully completed a diploma of Osteopathic Manual Practice at the Canadian College of Osteopathy (Toronto), and was awarded the ‘Louisa Burns Award for the Most Representative Thesis for the Advancement of Osteopathy in the Field of Basic Research'. In October 2013 Catherine graduated with her BSc Osteopathy (conversion course) from the British College of Osteopathy in London, England. Her professional experience includes almost 20 years of clinical practice, including working as Team Therapist and Chief Therapist for Gymnastics Canada on the World Cup circuit with the National Trampoline and Power Tumbling team. She acted as Medical Coordinator for the HSBC Multisport Canada triathlon series from 2004-2009 and has worked with a variety of high-performance athletes from Olympians to the everyday active individual. From 2014 to 2018 Catherine acted as the High-Performance Director for USA Gymnastics Trampoline and Tumbling program. Catherine worked as a Director with the Ontario Association of Osteopathic Manual Practitioners Board of Directors from 2012-2023, and served as President from 2016-2021. In 2023 Catherine joined Sheridan College as the Program Coordinator for the Honours Bachelor of Science Osteopathy degree, the first of its kind in Canada. Connect with Catherine: catherine.cabral1@sheridancollege.ca catherine@motionhw.ca Learn more about the Honours Bachelor of Science – Osteopathy at Sheridan College here.   CONNECT WITH US Watch our Masterclass where we show you a behind-the-scenes look at our top 3 business strategies and 3 mindset musts for osteopaths to grow your practice, fuller, faster. Get on the MBO Waitlist! The MBO is an 8-week LIVE interactive online program empowering you with a solid business framework to build your practice fuller and faster with confidence.  Follow us on Instagram Visit our website Did you enjoy this episode? We'd love to hear from you! Comment below, drop a view for the show and share it with friends and colleagues.    JOIN US AT INTEGRATION 2023 Live In-Person Symposium When: October 22nd, 2023 Where: Mohawk College, Hamilton, Ontario Virtual Symposium When: November 19, 2023   Learn more and get your tickets here: www.integrationsymposium.com    Integration 2023 will bring together, for the first time, Canadian Osteopathic Manual Practitioners who are experts in their field. Join us for a variety of content including informative plenary sessions, practice enhancement opportunities, hands-on sessions, and the opportunity to build community through their social event.   We will be speaking on “The Connected Practitioner” Kevin, Jason, and Sean are the creators of the MBO - Masters in Business for Osteopaths providing Advanced Mentorship for Osteopaths that bridges the gap between clinical education and real-world business success. We all graduate as osteopaths and do the same thing. We take continuing education courses thinking that once we learn the next new technique we will have a successful practice. The reality is that this doesn't work. In our combined 60 years of clinical experience, we have consistently found that what makes a successful practice is communication. The investment in building relationships with ourselves, our patients, and our communities results in the most successful practices. Join us to tap into the fundamentals of becoming a connected practitioner.   What you will take away from our time together: How to build a Winning Mindset. Discover simple techniques to align your business with your true vision Master your patient communication skills with the 3 E's (Educate, Empower, and Engage). Implement the 5-minute wrap up to guarantee sustainable growth Community Connection. Attract the community you are meant to serve by developing your unique voice

Early Academic Journey Elena's journey from studying physics and computer science to discovering her passion for life sciences and medicine. Overcoming challenges in academic pursuits and finding her calling in translational research. Translating Complex Science for Wider Audiences Practical techniques for effective science communication, emphasizing the importance of practice and feedback loops. Building community through volunteering and honing skills in event organization and speaker recruitment. The Multilingual Advantage Elena's experience as a trilingual communicator (Hebrew, English, Russian) and the benefits of immersing oneself in a language for effective communication. Overcoming initial translation challenges by thinking and generating content directly in the target language. mAcademia Podcast: Bridging Industry and Academia Exploring the journey from basic research to practical applications, and understanding career trajectories for scientists. Insights into the collaborative nature of academia and the importance of interdisciplinary ventures. Pursuing a PhD in genetics to becoming a passionate advocate for science communication and entrepreneurship. Emphasizing the importance of building communities and seeking out opportunities, especially for foreign students and scientists. Discussing her role as a board member of Science Abroad, a nonprofit organization that supports Israeli scientists living abroad. Highlighting the impact of community-building and mutual support in overcoming the challenges faced by international students. Resources mentioned in the episode: Nest Catalyst, an entrepreneurship program she co-founded to empower Israeli scientists in building companies based on research and science. mAcademia, a podcast exploring the bridge between the industry and academia to understand how basic scientific findings take shape into products and strategies and following the career paths of researchers who are in academia or outside of it ScienceAbroad, an Israel-based nonprofit organization that harnesses the power of senior Israeli scientists living abroad. Through its wide-reaching professional and social network  

When a DW co-investigation uncovers a path that leads from a German physics department to the Chinese military — and it involves technologies that could change the outcome of a war — it's time to ask uncomfortable questions.

For decades, researchers have utilized animal models to help predict the effects of a drug compound in humans.   With recent advances in technology and the passage of the FDA Modernization Act 2.0, researchers are increasingly looking at new methods to refine, reduce, and replace in vivo testing to advance drug candidates. However, one important question remains – how are all these modern advancements and laws driving progress in drug discovery?   Find out as Michael Templin, a member of Charles River's Scientific Advisory Services team, joins us for a look at the impacts of this legislation on regulatory submission for biosimilars, how improving animal welfare will make drug development better, and what knowledge a CRO can bring to optimize projects.Show Notes Animals in Research | Charles River  Basic Research | Charles River  Research Models and Services  FDA Modernization Act

Денис Артамонов, кандидат исторических наук, доцент и докторант кафедры теоретической и социальной философии СГУ им. Н.Г. Чернышевского. Сфера научных интересов: история рекламы, историческая память, цифровая мифология, социальная эпистемология, исследование интернет-мемов, компьютерных игр, сетевой литературы. Лектор Российского общества «Знание», спикер и эксперт проекта «Цифровой мост 2.0», эксперт Института совместного проектирования и экспертизы, член отборочной комиссии Фестиваля детского и юношеского кино «Киновертикаль, член РОИФН, РФО, СРОО СРК «Кинотраектория", руководитель и участник грантовых проектов РФФИ и РНФ, креативный фотограф, блогер. Автор книги в соавторстве с С. В. Тихоновой «Историческая память в социальных медиа» (СПб., 2021) и «Петр I в медиапамяти» (Саратов, 2022). Denis Artamonov, PhD in Historical Sciences, Associate Professor and Doctoral Candidate, Department of Theoretical and Social Philosophy, SSU. N.G. Chernyshevsky. Research interests: history of advertising, historical memory, digital mythology, social epistemology, research on Internet memes, computer games, online literature. Lecturer of the Russian society "Knowledge", speaker and expert of the "Digital Bridge 2.0" project, expert of the Institute for Joint Design and Expertise, member of the selection committee of the Festival of Children's and Youth Cinema "Kinovertical", member of the ROIFN, RFO, SROO SRK "Kinotraektoriya", head and participant of grant projects of the Russian Foundation for Basic Research and the Russian Science Foundation, creative photographer, blogger, author of the book “Historical memory in social media” (St. Petersburg, 2021) and “Peter I in media memory” (Saratov, 2022) in collaboration with S. Tikhonova. FIND DENIS ON SOCIAL MEDIA VKontakte | Odnoklassniki | YouTube ================================SUPPORT & CONNECT:Support on Patreon: https://www.patreon.com/denofrichTwitter: https://twitter.com/denofrichFacebook: https://www.facebook.com/mark.develman/YouTube: https://www.youtube.com/denofrichInstagram: https://www.instagram.com/den_of_rich/Hashtag: #denofrich© Copyright 2023 Den of Rich. All rights reserved.

Drs Stanley Cohen and Christopher Ritchlin discuss advances in basic research for psoriatic arthritis, including new research using a humanized mouse model, combination therapy trials, and more. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984269). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview Transcriptional Signature Associated With Early Rheumatoid Arthritis and Healthy Individuals at High Risk to Develop the Disease https://pubmed.ncbi.nlm.nih.gov/29584756/ DC-STAMP: A Key Regulator in Osteoclast Differentiation https://pubmed.ncbi.nlm.nih.gov/27018136/ Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging https://pubmed.ncbi.nlm.nih.gov/34204773/ Transcriptome Fact Sheet https://www.genome.gov/about-genomics/fact-sheets/Transcriptome-Fact-Sheet Tumor Necrosis Factor Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK482425/ Inverse Psoriasis https://www.psoriasis.org/inverse-psoriasis/ Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-tool-presto-development-and-performance-of-a-new-scoring-system-for-psoriatic-arthritis-risk/ Efficacy of Guselkumab, a Selective IL-23 Inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk Cohort (PAMPA): Protocol of a Randomised, Double-Blind, Placebo Controlled Multicentre Trial https://pubmed.ncbi.nlm.nih.gov/36564123/ Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review https://pubmed.ncbi.nlm.nih.gov/33301128/ Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00034-6/fulltext Prevention of Psoriatic Arthritis: The Next Frontier https://www.thelancet.com/pdfs/journals/lanrhe/PIIS2665-9913(23)00055-3.pdf Ultrasound Power Doppler and Gray Scale Joint Inflammation: What They Reveal in Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/31304659/ Consensus Terminology for Preclinical Phases of Psoriatic Arthritis for Use in Research Studies: Results From a Delphi Consensus Study https://pubmed.ncbi.nlm.nih.gov/33589818/ Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/32602263/ Abatacept Reverses Subclinical Arthritis in Patients With High-Risk to Develop Rheumatoid Arthritis -- Results From the Randomized, Placebo-Controlled ARIAA Study in RA-at risk Patients https://acrabstracts.org/abstract/abatacept-reverses-subclinical-arthritis-in-patients-with-high-risk-to-develop-rheumatoid-arthritis-results-from-the-randomized-placebo-controlled-ariaa-study-in-ra-at-risk-patients/ Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/ Arthritis Mutilans https://pubmed.ncbi.nlm.nih.gov/23430715/ Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results From a Real-World Survey in the USA and Europe https://pubmed.ncbi.nlm.nih.gov/35032324/ Disease Modifying Anti-Rheumatic Drugs (DMARD) https://pubmed.ncbi.nlm.nih.gov/29939640/ Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis https://pubmed.ncbi.nlm.nih.gov/30499418/

A major challenge in academic neurology departments is supporting basic and translational research.  As clinical revenue becomes increasingly important to the financial health of Neurology Departments, supporting non-clinical activities such as teaching and research has become increasingly difficult. This is especially problematic for physician scientists, many of which require several years of both salary and research support. So how can you build research in your Department?

Kari and Don are joined once again by Dr. Jurick as he discusses basic research and the research focus of his laboratory and provides insight into the next few episodes. Episode Host/Speakers: Don Seifrit (host)Kari Peter (speaker)Wayne Jurick (speaker)Photo Credit: Kari Peter, Penn StateMake sure you sign up to get notified of future Extension events for tree fruit growers! Sign UpFlight Seasonalities of Main Fruit Pests During the Growing SeasonWeekly update information on trap counts for Codling Moth, Obliquebanded Leafroller, Oriental Fruit Moth, Redbanded Leafroller, Spotted Tentiform Leafminer, and Tufted Apple Bud Moth during the 2023 growing season.

From 2016, * Raymond Damadian on RSR: Real Science Radio co-host Bob Enyart interviews Raymond, inventor of the MRI magnetic resonance imaging device. If you love learning about the history of scientific discovery, inventions, and absolute truth, you will absolutely LOVE listening to today's program! A year ago Bob logged onto Wikipedia to edit the entry on the MRI after noticing that the events listed in the History section of that article were out of chronological order. After making a minor change, moving the sentence about Dr. Damadian earlier in the section to where it belonged chronologically, Bob noticed that the heavy-handed Darwinist editors at Wikipedia, obviously seeking to diminish the contribution of young-earth creationist Damadian, reversed Bob's correct and to the day of our interview, they insist on presenting the History of the MRI out of chronological order. Selah. * Upright MRI: Dr. Damadian explains the benefits of the Upright MRI. This technological advance help doctors treat patients with spinal column ailments, MS, and many other health challenges. Just click on the image for more information, and check out the doc's informative website at fonar.com. * rsr.org/mri: If you'd like to share today's show, feel free to use our permanent URL for this program, rsr.org/mri. And at rsr.org/mri-2 check out next week's conclusion to this interview! Thanks! * Update -- Upright MRI and MS Diagnosis and Treatment: Hear the October 7, 2016 RSR follow-up program with Damadian at rsr.org/mri-ms on his important discoveries and recommended treatment for multiple scleroris. * Update MRI Used for Basic Research: The Illustra Media video, Metamorphosis, uses MRI to explore the development of the butterfly inside the chrysalis. You'll just LOVE that DVD and you can get a copy, thanks to Illustra, Dr. Damadian, and God, at rsr.org/butterfly.  * Please Support RSR: Please consider making a one-time or automatic monthly donation by clicking on the Store tab (above, which is at rsr.org) or call 1-800-8Enyart (836-9278) to help us reach our vital $30,000 goal for our February 2016 telethon to keep RSR broadcasting for another year! * Damadian Not a "Real Scientist" But an MD: Dr. Damadian and Bob Enyart discussed a couple of the objections that the scientific community had to recognizing him as the inventor of one of the greatest advances in physics in the realm of medical science. One objection is that he is a biblical (i.e., young earth) creationist. A second objection is that Raymond Damadian is not a "real" scientist but only a medial doctor. Bob pointed out a parallel instance whereby creationist will ignore the work, including astounding confirmed discoveries, of Dr. Walt Brown, PhD from MIT in mechanical engineering, because he is not a professional geologist. [After today's program, during their off-air discussion, Dr. Damadian happily agreed to receive a copy of RSR's Global Flood and Hydroplate Theory video. If you enjoy these excerpts of that educational presentation, please consider getting a Blu-ray or DVD or download of the full video!

From Leviticus, Isaiah and Luke. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

If your business is location specific, then you shouldn't be chatting to people on the internet who aren't close enough to do business with you. It might not amount to anything if the nature of the opportunity requires that both of you be in the same city to pull it off. Do some basic research on the profile or the bio by at least making sure you are in the same city

Section on Biologics & Basic Research members, Zorica Buser, PhD, MBA and W. Mark Erwin, DC, PhD discuss whether or not there is any evidence that can address differences in the pain experience of patients living with DDD vs normal ‘ageing'. Is it disc or is it endplates? If it is disc, annulus, nucleus, or both? Disclosures: Buser, Zorica: Board of Directors: LSRS (Nonfinancial, Co-chair of Educational Committee); Consulting: Cerapedics (B, Outside 24-Month Requirement); Research Support (Staff and/or materials): Medical Metrics (B, Paid directly to institution/employer), Next Science (F, Paid directly to institution/employer), SeaSpine (F, Outside 24-Month Requirement, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement), NASS (Travel Expense Reimbursement). Erwin, William Mark: Board of Directors: Notogen (Stock options and salary support only); Grants: Skoll Family Trust (G, Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock options only); Stock Ownership: Notogen (3,000,000 Shares, 33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

This podcast episode features a team of K-State lipid researchers to help us understand food through basic lipid research and how this work improves what we eat. For this conversation, we welcome Ruth Welti, distinguished professor of biology and director of the Kansas Lipidomics Research Center; Kathrin Schrick, associate professor of biology; and Timothy Durrett, associate professor of biochemistry and molecular biophysics.

Without funding for basic research, many space workers are out of jobs.   On this week's episode of Space Connect Podcast, host Bella Richards is joined by Professor Phil Bland from Curtin University, who is also the director of the Space Science and Technology Centre (SSTC).    Professor Bland reveals that Australia needs to aim higher in funding basic research to make more discoveries, send more homegrown spacecraft into orbit, and to keep people in their jobs.    Bella and Phil also chat about Curtin's Binar-1 launch last year, the challenges that came with it, and how it proved that Australia does have all the space capabilities.

Dr. Gregory Lesinski is a Professor and the Vice-Chair for Basic Research in the Department of Hematology and Medical Oncology at Emory University. Dr. Lesinski earned his PhD in Biomedical Sciences from The Medical College of Ohio in Toledo, Ohio. He obtained his MPH in Clinical Investigation from The Ohio State University in Columbus, Ohio and completed his post-doctoral training at The Ohio State University and joined the faculty there before being recruited to Emory. Today he shares his professional journey and provides insights into his career as a translation researcher. Credits: Our thanks to Dr. Lesinski for being on the podcast. Follow Dr. Lesinski on Twitter: @LesinskiLab Dr. Lesinski's faculty page: https://winshipcancer.emory.edu/bios/faculty/lesinski-gregory-b.html Host: Bejan Saeedi Co-Host and Audio Engineer – Joe Behnke Executive Producer and Social Media Coordinator – Carey Jansen Executive Producer – Michael Sayegh Associate Producer – Josh Owens Faculty Advisor – Dr. Brian Robinson Twitter: @behindthescope_ Instagram: @behindthemicroscopepod Facebook: @behindthemicroscope1 Website: behindthemicroscope.com

Messages from the Gods Messages that travel over pure light No more middle man, we can put you in touch with God himself DOT.CONNECTOR.PODCAST by BMC This amazing video is proudly presented by our sponsor || SIZZLE CITY || Strings of Bling and Other Shiny Things || Call or Click Today || www.SizzleCity.com || 626.274.6028 || Hot Products / Sizzling Prices || Over the last few weeks we are learning more about the dome than ever before. As we gain more and more useful and important pieces of video from different sources showing the holographic canopy of Earth, the great waterfall, the edge of earth, buildings and structures which run the construct and the great machine which runs it all along with it's power source do we realize that the dome has been showing us this stuff for years. Of course we didn't know what we were looking at until we saw it in NASA footage from STS missions back in the 90s. About the Dome The dome is a collection of only three items which is a less expensive alternative to something called the Santilli Telescope Method. The Santilli Method is the only known and proven method of recording, documenting and researching alternative and parallel universe as well as invisible terrestrial entities that exist all around us here on Earth and here within our universe. The Santilli Method was discovered by a Jesuit and Vatican Astronomer by the name of Ruggero Maria Santilli from the Institute for Basic Research. As I'm sure you can already tell from the sound of it - there's absolutely nothing basic about his institute or his research. Mr. Santilli did something very basic to a very well-known telescope and that's probably the basis for his institutes's name. He took the end lens on Galileo telescopes and turned it concave. When he did - it opened an unknown universe that's existed all around us since the days of creation. The ITEs we all have the power to record, document and track by all intensive purposes could be the angels we've only read about in the Bible, the Torah, the Quran and many other religious scriptures across the world and throughout history. Let's hear straight from the astronomer and inventor himself in one of his existing physics papers devoted to the use of this Santilli Telescope in the finding and recording of ITE-1 and ITE-2 entities here in our world where they've been since the beginning of time, since the days of creation. I Wrote This for the Show and Wanted to Share it with You All We've returned from battle, beaten, bruised, bleeding but victorious. We drink litres of mead to dull the pain, burn our wounds to stop the bleeding. Drag the bodies of the fallen to the doors of the palace and make them easier to find by lighting them on fire. The smell of burning flesh just makes me hungrier than swinging this ax all damn day lopping off the heads of enemies. Kicking them downhill and laughing in between waves of dead men walking rushing towards us with no experience in these sorts of things. What were they thinking recruiting children to do their bidding? It's never a problem killing - kids just give you worst dreams but there were already going to be dreams either way. The steamed bore sits in the center of the mess hall, apples, potatoes, onions, roots, bulbs and tomatoes piled high around it. Norsemen dig in without washing up. Burying their hands into the side of the boar and yanking out fistfuls of meat. Slugging it down with mouthfuls of mead. Killing makes every norseman horney and slavegirls are a plenty in the ranks downstairs. First one gets the best, last ones off the field get the mess we leave behind on them. I can actually see the blood rushing down my face since I took an arrow to the head this morning. It made it impossible to see. I picked up one of the heads I chopped and used his tail to clean in the cracks of my eyes. That helped a lot and bought me a lot of time on the killing fields. I think I broke a toe from kicking bodies out of the way and off the cliff. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/bmc-dotconnector-podcast/message

Permafrost, or ground that has been frozen for at least two years, covers roughly a quarter of the Northern Hemisphere. And it is teeming with microbes, including many with unique characteristics that have allowed them to adapt to extremely low temperatures and survive for decades. As climate change threatens to thaw permafrost and revive these microbial multitudes, ERDC is conducting extensive basic research to better understand these tiny organisms, comprehend what will happen when they are activated, and harness their special powers for new technologies. On the latest episode of the Power of ERDC podcast, we talk with Dr. Robyn Barbato, a research microbiologist at ERDC's Cold Regions Research and Engineering Laboratory, about how this research will support military operations in extreme cold regions and will improve our understanding of the impact of climate change on Arctic ecosystems. We discuss the hidden power of these frozen microorganisms (3:18), why this research is important to the military (6:32), how it can improve the understanding of climate change (7:46), how ERDC's people (18:05) and world-class facilities (20:10) enable this research, and what the future holds for this effort (35:09). We also explore how these living microbes can be used for various technologies and applications, such as environmental sensing, cleaning contaminants and producing electricity (22:27). Finally, we talk about basic research and what makes it important (12:26). Visit https://www.PowerofERDCPodcast.org for more information.

Every creditable educator in Kink, BDSM or any subject tells you to do your research, Our guest GargoyleLink provides a examples and resources for researching information about the BDSM lifestyle. About Us: Constantly Learning in BDSM, Kink and Alternative Lifestyles is important, no one believes that more than CancerPhase Productions. We host regularly schedule classes with new and renowned educators through our discord including some exclusive classes not available on our podcast. Join us and experience a online community focused around education. --- Send in a voice message: https://podcasters.spotify.com/pod/show/cancerphase/message Support this podcast: https://podcasters.spotify.com/pod/show/cancerphase/support

There was a LOT of news about the omicron variant last week. But which of it was actually important? Also, why are scientists in Germany growing thousands of miniature human brains with eyeballs on them?

Dustin Updike is  an Associate Professor at MDI Biological Laboratory. Dustin's work looks at how stem cells maintain pluripotency -- the capacity to become other cell types in the body. Dustin and his team use some of the newest and most innovative biological research tools - including CRISPR - to study C. elegans nematodes. More about the Maine INBRE program:  https://inbre.maineidea.net/. And you can see some images of C. elegans at https://youtu.be/byFjiXBamKM.~~~~~~The 2022 Maine Science Festival Call for Ideas is open (https://www.mainesciencefestival.org/call-for-ideas) until November 19, 2021. Tickets are now on sale for the 2022 Headliner: The Warming Sea - an exploration of Hope in the face of the climate crisis. (thewarmingsea.me) - March 19, 2022, 7pm, Collins Center for the Arts.~~~~~~The Maine Science Podcast is a production of the Maine Science Festival. It was recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. Edited and produced by Kate Dickerson; production support by Maranda Bouchard and social media support from Next Media. The Discover Maine theme was composed and performed by Nick Parker.  If you want to support the Maine Science Podcast and/or the Maine Science Festival, you can do so at our website mainesciencefestival.org either at our donation page OR by getting some MSF merchandise through our online store.  Find us online:Website - Maine Science FestivalMaine Science Festival on social media: Facebook    Twitter     InstagramMaine Science Podcast on social media: Facebook    Twitter     InstagramMaine Science Festival Store - https://bit.ly/MSF-storecontact us: podcast@mainesciencefestival.org© 2021 Maine Science Festival

Michael Hamblin, Ph.D. is a world leading expert in photobiomodulation and photodynamic therapy. His roles have included Principal Investigator at the Wellman Center for Photomedicine, Massachusetts General Hospital, and an Associate Professor at Harvard Medical School. He has published over 422 peer-reviewed articles, is Editor in Chief of "Photoiomodulation, Photomedicine and Laser Surgery" and Associate Editor for 10 journals. Michael has authored/edited 23 textbooks on photo dynamic therapy and photomedicine and is a member of the Society of Photo-optical Instrumentation Engineers where he was elected as a Fellow in 2011. He also received the 1st Endre Mester Lifetime Achievement Award in Photomedicine from the NAALT in 2017, the Outstanding Career Award from the Dose Response Society and 1st Ali Javan Award for Basic Research from WALT in 2018.-Follow Michael's WorkMichael's Journal-Follow My WorkWebsiteConsultationInstagramYoutubeSpotifyApple PodcastsLinkedin

This week's episode features special Guest Host Mercedes Carnethon, as she interviews author Sung-Min Cho and Associate Editor Marc Ruel as they discuss the article "Cerebrovascular Events in Patients with Centrifugal-Flow Left Ventricular Assist Devices: A Propensity Score Matched Analysis from the Intermacs Registry." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well, Carolyn, this week's feature, we're going to look at centrifugal flow, left ventricular assist devices and cerebrovascular events. But before we get to the feature, how about we grab a cup of coffee and jump into some of the other articles in the issue? And maybe how about I go first? Dr. Carolyn Lam: All right. I got my coffee. Dr. Greg Hundley: So my first paper comes from Professor Dali Luo from Capital Medical University. And it's pertaining to calsequestrin-1. So calsequestrin-1, and calsequestrin-2 isoforms buffer calcium and regulate its release from the sarcoplasmic reticulum of skeletal and cardiac muscle. Human inherited diseases associated with mutations of calsequestrin-1 or 2 include malignant hyperthermia and environmental heat stroke and catecholamingergic polymorphic ventricular tachycardia. However, patients with hypothermia, environmental heat stroke events often suffer from an arrhythmia for which the underlying mechanism remains unknown. Dr. Carolyn Lam: Wow. Okay. And what did the current paper do and find? Dr. Greg Hundley: Great, Carolyn. So what the authors found, calsequestrin-1, the skeletal isoform of it is indeed expressed in cardiomyocyte sarcoplasmic reticulum for mirroring in human hearts, mostly presenting as a polymeric form and interacting with the ryanodine 2 receptor in ventricles. Second, calsequestrin-1 deficiency cause sinus tachycardia in basal conditions. And this is a novel finding which may be associated with sinus beat regulation and ventricular arrhythmia as an independent arrhythmogenesis if a high concentration of volatile anesthetics are used. Next, these volatile anesthetics and heating to 41 degrees C can directly induce calsequestrin-1 oligomerization, thereby causing enhancement of diastolic calcium leak and premature calcium transience through a reduced regulatory effect of calsequestrin-1 on ryanodine 2 activity. And so Carolyn, this novel mechanism underlying the arrhythmia occurring in patients with malignant hypothermia or environmental heatstroke episodes may provide different strategies for heart disorders as an independent profile in these syndromes. And finally, the finding of calsequestrin-1 confirmational change induced by triggers in those with malignant hyperthermia and environmental heatstroke could lead to novel therapeutic approaches to prevent these types of episodes. And that may also very, very useful in treatment of heatstroke.   Dr. Carolyn Lam: Wow. Thanks Greg. Well, moving from this preclinical world to a very common clinical question of the diagnosis of acute myocardial infarction. Now we know that in patients presenting to the emergency department with symptoms suggestive of an MI, the European Society of Cardiology zero and one hour algorithm is recommended by current ESC NSTEMI guidelines with a class one recommendation. Now, what this does is it combines a very high safety for early rule-out and high accuracy for rule-in allowing a definite triage of about 70 to 75% of patients using the zero in one hour sample. Dr. Carolyn Lam: However, what is the most appropriate management of the 25 to 30% of patients who remain in the gray observed zone? So this is the question that the current paper addresses. Now to answer this, we also need some more background that a single center pilot study previously of patients in the observed zone had derived a cutoff of seven nanograms per liter for a zero and three hour high sensitivity cardiac troponin T change to identify patients also eligible for early rule-out or rule-in of NSTEMI. So the current study that we're talking about in today's issue from Dr. Christian Mueller from Cardiovascular Research Institute in Basil, Switzerland, and colleagues, really aimed to externally validate that previously proposed seven nanogram per liter change cutoff, and if necessary derive and internally as well as externally validate some new criteria for these patients in the observed zone of the ESC zero in one hour algorithm. Dr. Greg Hundley: Wow, Carolyn, so we're learning a lot about cutoff values and also algorithms here with high sensitivity cardiac troponin T. So what did they find here? Very interested to hear. Dr. Carolyn Lam: So in two large prospective multicenter diagnostic studies, they found that the proposed zero and three hour high sensitivity cardiac troponin T change of seven nanogram criteria, unfortunately provided suboptimal safety for ruling out NSTEMI in patients remaining in the observed zone of the ESC zero and one hour algorithm. So this had a sensitivity of only 33% and missed 80 patients with NSTEMI. So they derived their own novel criteria based on zero and three hour samples. And these novel criteria combined a three hour high sensitivity cardiac troponin T concentration of less than 15 nanograms per liter and a zero and three hour absolute change cutoff of four nanograms per liter. Dr. Carolyn Lam: And that combination provided a high safety for ruling out NSTEMI in these patients in the observed zone and with a sensitivity of 99% missing only one patient with NSTEMI. Another further thing they found was at a zero and three hour cardiac troponin T absolute change of greater or equal to six nanograms per liter triage, 63 patients, or 11% towards rule-in thus resulting in a specificity of 98%. So in summary, this novel criteria based on zero and three hour sample seemed to balance safety and efficacy well for the further decision making in patients who are remaining in the observed zone after the zero and one hour cardiac troponin T algorithm. Internal validation of these novel criteria and external validation in an independent international cohort showed robustness of performance metrics and further strengthen its possible clinical use.   Dr. Greg Hundley: Very nice, Carolyn. Lots of data there, and hopefully very important clarification on both the zones as well as the cutoff values for using cardiac troponin T. Well, Carolyn, my next paper again comes from the preclinical science world and it's from Dr. Anne Eichmann at Yale University School of Medicine, and it pertains to activin receptor-like kinase 1. And we're going to call that ALK1.   Dr. Greg Hundley: Kinase 1 and we're going to call that ALK1. And it's an endothelial transmenbrane serine threonine kinase receptor for BMP family ligands that plays a critical role in cardiovascular development and pathology. And loss of function mutations of the ALK1 gene cause type 2 hereditary hemorrhagic telangiectasias, a devastating disorder that leads to arteriovenous malformations. Dr. Carolyn Lam: Oh, okay. And what did the authors find? Dr. Greg Hundley: Dr. Carolyn Lam, ALK1 mutants displayed defective polarization against the direction of blood flow in capillary and venous endothelium as well as increased integran VEGF receptor 2 mediated P13K activation of YAP/TAZ signaling. Dr Carolyn Lam: Okay, Greg, that was super summarized but what are the clinical implications? Dr. Greg Hundley: Carolyn, pharmacological integrin inhibition using cilengitide or ATN-161, or YAP/TAZ inhibition using verteporfin, prevented AVM malformation in ALK1 mutant mice. And therefore for this study, the authors revealed that integrin and YAP/TAZ were novel affectors of ALK1 signaling in AVM pathogenesis that might be targeted for AVM treatment in patients with hemorrhagic telangiectasias. Dr. Carolyn Lam: Thank you, Greg. Well, let's review what else is in today's issue. There's an exchange of letters between Doctors Amadio and Valentine on cell-free DNA to detect heart allograph acute rejection. There's an AHA Update paper by Dr. Churchwell on preemption, a threat to building healthy, equitable communities. There's a Research Letter by Dr. Merkler on the association between cervical artery dissection and aortic dissection. Dr. Greg Hundley: And Carolyn, I've got a paper from Professor Daniels regarding the Clinical Implications of Basic Research getting inside the engine, the myosin modulation of hypertrophic cardiomyopathy and systolic heart failure. And then finally, there's an In Depth piece from Dr. Viskin entitled, “Polymorphic Ventricular Tachycardia: The Terminology, mechanism, diagnosis and Emergency Therapy.”   Dr. Carolyn Lam: Nice. Well, let's go on to our feature discussion. Can't wait. Dr. Greg Hundley: You bet.   Dr. Mercedes Carnethon: Welcome to this episode of Circulation on the Run, our podcast where we have an opportunity to talk with the authors of some of the top articles within our journal for a given week. And we've chosen today to focus on a set of articles, one of which is led by Dr. Sung-Min Cho from the Johns Hopkins University. And I'm really excited to have you with us today, Dr. Cho and joining us as well as the associate editor, Dr. Marc Ruel who handled the paper. And my name is Mercedes Carnethon from the Northwestern University's Feinberg School of Medicine. I guess without further ado, welcome to you both and we'll just jump right into it. Dr. Mercedes Carnethon: Dr. Cho, I'd love to hear a little bit more about your paper today. What made you choose to pursue this particular topic and what really inspired you? Dr. Sung-Min Cho: Thank you so much for the invitation and opportunity to talk today. During my training as a neuro person, I'm a neurointensivist by training and neurologist. I noticed that we are getting a lot of consults for LVAD associated strokes. When I took a closer look at the ENDURANCE trial, very showed really 29.7% stroke rate at two years and a few years later, we had this MOMENTUM 3 trial, which showed HeartMate 3 device had 10% stroke rate at two years. And we realized that a stroke is a major issue in this population and I wanted to study the incidence respecters and outcome of this strokes in LVAD population. However, despite the many observational studies in the past, we were really interested in looking at device specific stroke risk for current continuous flow LVADs and we wanted to look at the device specific risk and prevalence of these patients balancing co-morbidities each cohort. And that's why we conducted this study. Dr. Mercedes Carnethon: Great, well Sung-Min, it's not often that as an epidemiologist and cardiovascular epidemiologist that I actually get to talk with neurointensivists and get their insights on the importance of their work. Can you tell me a little bit about what you found and whether it surprised you? Dr. Sung-Min Cho: Population, we used the Intermacs registry database. This is well established database as all cardiologists and cardiothoracic surgeons know, and we defined a neurologic adverse event as stroke plus TIA, transient ischemic attack. We used a propensity score matching analysis to assess the association of HVAD with stroke risk, to balance for pre-implant risk factors. And basically after performing propensity score matching, we found that hazard of stroke was higher for patients with HVAD device compared to HeartMate 3. We kind of expected this based on the randomized control trials in the past but there was no head to head comparison between these two cohorts. This study really confirmed our suspicion that HeartMate 3 actually had lower hazard of a stroke compared to HeartMate 3. Dr. Mercedes Carnethon: Well, thank you so much. It's a really great explanation. And for those who haven't had a chance to dig into the issue yet, I really encourage you to read the piece. I found it to be very instructive. And I'm interested as well, Mark in your take about what excited you about this piece. Dr. Marc Ruel: Well, thank you very much Mercedes and Sung-Min it's really a pleasure to have you with us today. As you know, this has been a very impactful paper and you were very kind to share with us the study around your idea as to why you wanted to evaluate this question but even more than your idea and what led to the completion of the paper are the implications of your paper. And I think it would be great if you shared with us a little bit, what has been the path that your paper has led to and including amongst others, very likely a decision by the Medtronic to pull the HVAD out of market. It's interesting that your data, to my knowledge, correct me if I'm wrong, were presented first at the annual meeting of the Society of Thoracic Surgeons in January, 2021. And again, I want to reiterate that Circulation's very thankful that you chose to send your paper to our journal and we feel that it will give it full justice, like many other journals of would have had but we're really excited to have received your paper and give it the fullest consideration. Dr. Marc Ruel: Can you tell us a little bit about the implications and for lack of a better word, the storm that your paper has created in the field and your take on it? Dr. Sung-Min Cho: Right. That's a great question. Thank you for that. Like I said, as a neurologist, we see these patients after complication, patients having stroke and then we see these patients and we always wanted, cardiologists and cardiothoracic surgeons and neurologists, we always wondered which device carried more risk for stroke and TIA. And really our group actually worked on many papers in the past looking at single institutional data and also systematic review meta-analysis looking at this topic, but really HeartMate 3 came along a couple years ago, more recent device so we didn't have a lot of data. Dr. Sung-Min Cho: So intermex registry really helped since we didn't have a lot of data. So, INTERMACS Registry really provided opportunity for us to look at this specific question, really balancing those two chords to look at the risk of stroke in this HeartMate 3 and HVAD. And when we did that two years ago, we submitted a proposal to INTERMACS, and Dr. Kirklin from UAB, he really helped us to look at this data closely with his statistical team. And we had really a thorough statistical method to perform a propensity matching analysis. And we finally finished the analysis and presented in annual STS meeting in January, and it did really trigger a lot of attention to a lot of academic institutions and people who are practicing LVAD, and after that, when we finally submitted this paper to Circulation, we had to have a lot of discussion in between FDA and the Medtronic and discussing this implication of this paper. When it was finally published in Circulation, we are happy that there's a lot of attention and we made it through. Dr. Marc Ruel: Well, thank you, Dr. Cho, and maybe for the listener of this podcast, I would like to reiterate some of the salient points of your paper essentially, and correct me if I'm wrong, over 6,200 patients were included, about roughly 3,000 patients per group comparing the HeartMate 3 versus the HVAD. Dr. Marc Ruel: Now, as you alluded to the HVAD is the more ancient device, if you will. So there's a slightly longer follow-up, around 12 months on median, versus nine months with the HeartMate 3. And there's adjustment that has been made for this. And I think to me, really the key finding is that in the early acute phase around implantation, there is no real difference with regards to the risk adjusted incidents of neuro adverse events. However, once you pass the early implantation acute phase, in the chronic stable phase, there starts being really a signal that is detrimental to the performance of the HVAD versus the HeartMate 3. And I think your hazard ratio, correct me if I'm wrong, it's around 5.7 for neuro adverse events. Dr. Marc Ruel: So this is a very compelling hazard ratio, even coming out of an observational study with all the careful attention that you provided to adjust for residual confounding, et cetera. Dr. Marc Ruel: So obviously this is a very strong finding, but I would like you to perhaps comment on this, the patients are not the same. There's some indication that the HVAD patients may have been a little sicker, more RV dysfunction, more tricuspid regurgitation, higher INTERMACS-1 incidents more often on ECMO prior to an implant. What are your thoughts about this? Dr. Marc Ruel: Obviously, you've been very careful and the reader will note in the paper that many attempts have been made to account for those. But please give us your take around that 5.7 hazard ratio for neuro adverse event that you found. Dr. Sung-Min Cho: Right? In fact, we were really being careful adjusting those compounders. So we did a propensity matching has a primary analysis, but as you pointed out, as a secondary analysis, we wanted to look at multi-variable logistic regression analysis, looking at multi-hazard analytics. And when we did the secondary analysis, as you said, in the beginning early hazard period, the risk was similar, as time went on in the constant hazard period, the hazard ratio was 5.7 for HVAD compared to HeartMate 3, which gives a much higher risk of stroke and TIA for those patients with HVAD compared to HeartMate 3. Dr. Sung-Min Cho: So, that was really convincing to us. Confirming the findings from propensity matching analysis, showing that same findings were consistent throughout the different analysis. As we pointed out, HVAD patients actually were sicker, they had more ECMO, and they had more ventilation requirement or sicker patients INTERMACS level. Those are all carefully balanced in both propensity matching analysis and also multi-hazard analytics. And both of these analysis consistently showed that HVAD carried more risk of TIA and stroke compared to patients with HeartMate 3. Dr. Mercedes Carnethon: Thank you so much Sung-Min. You know what excites me as I think about choosing articles for journal clubs, when we're working with our trainees, the propensity matched approach and comparing it directly with what you're getting from multi-variable regression really provides an excellent methodological strategy to be able to generate results from these real world studies where it's not a randomized trial of who received which device, but we're able to yield practical conclusions that are actionable based on these findings when we have these well done analyses. And Marc alluded earlier to the actions that were taken in response to the findings from your study. Can you expand on those just a little bit more? Sung-Min Cho: Of course. So I guess, I don't know the real backstory, what was going on behind the scene, but I know for sure that STS leadership and INTERMACS leadership, they had a lot of discussion with the company who made HVAD device and also FDA, and I know that this study, the results of this study contributed to the decision they made back in June, pulling up HVAD device from the market. Sung-Min Cho: So I'm glad that this study could contribute to the science and hopefully this will help the patients in the future for device selection. So yeah. Dr. Marc Ruel: Sung-Min, I think it's fair to say that your study is probably, if not the most impactful in the field of ventricular assist devices, and I probably would personally think that it is, if not the single most impactful, certainly one of the two or three that are the most impactful. So congratulations to you and your team. Dr. Marc Ruel: If you still have a minute or two, I had a couple of more secondary questions? Dr. Marc Ruel In your analysis I noted that in the early acute phase, there are some protective predictors, such as performing the LVAD implant by sternotomy, which essentially results in about half of the neuro adverse events that you would otherwise observe. So I was a little intrigued by that. And high volume centers had about 1.8 hazard ratio. I suspect that's probably reflective of baseline risk and more acute illness in those patients coming. But if you have a chance, I'd love to hear your thoughts around this? Dr. Sung-Min Cho: Yeah, that's exactly what we thought actually is, initially we thought, hypothesized that surgical volume, the center volume will be associated with lower risk of stroke, but it was the other way around. But as you said, probably higher volume centers were getting sicker patients, so that's the association probably we were getting in the analysis. And we wanted to adjust for surgical techniques, sternotomy versus thoracotomy, and even after adjusting for that, HVAD remained a significant hazard per stroke, which showed in the table two and three, I think in the manuscript. Dr. Sung-Min Cho: And if I may, I want to say these couple of things. In the raw number, in the 6.4% of patients actually had TIA and strokes, neurological adverse events in HeartMate 3, at one year based on our study. And the risk goes up with a longer follow-up time of course. Moment3 trials had two-year follow-up, about 10% had stroke. And this is still, after HVAD is taken off the market, still there's a significant risk for stroke in these patients and based on autopsy and MRI studies although there is a very small studies--MRI studies, although they're a very small series, studies looking at MRI'd brains after explantation of LVAD. And it shows actually more than 95% of patients have cerebral micro bleeds, which is a marker for small vessel disease in the brain. I think this is an important issue, and although we show that one device had a lower risk of stroke, still question remains, are these patients have a high risk of stroke? And there is a need for improving biomedical engineering aspect, and I'm sure cardiologists and cardiothoracic surgeons know much better than I do regarding hemo-compatibility, especially for stroke. Dr. Sung-Min Cho: There is also a dire need for early detection and intervention for these events to improve the outcome for these patients, because once you have a stroke, the outcome is devastating, right? So I think there needs to be better medical management, neuroprotective agent, as well as neuro- monitoring methods, maybe biomarkers to predict stroke or TIA to come so we can intervene and prevent these really devastating complications. Dr. Marc Ruel: Mercedes, if I'm so allowed, I do have one final comment and question. Dr. Mercedes Carnethon: Most definitely. This has been delightful, so yes. Dr. Marc Ruel: Wonderful. So, first, Sung-Min, I want to thank you for working with us. We at Circulation were interested in your paper. You may recall you and I spoke on the phone offline when the decision to revise was made, and we went carefully over what the editors were anticipating would make your paper even better. And you were very responsive. You and your co-author's team were tremendous. And I think the paper that we have before us is absolutely very, very insightful and very important. And obviously tremendously impactful. So I want to thank you again for that. Dr. Marc Ruel: And my question is probably the very difficult question which is in everybody's mind at this point and I would like your take as a neurointensivist. You have someone who you have to care for who has a well-functioning HVAD, two years post implant. What would you recommend in terms of optimization for the prevention of neural adverse events? I realize we don't have all the information, but you are one of the few experts in the world who can probably provide us with a very valid take on this very difficult question. Dr. Sung-Min Cho: Yeah, it is indeed a difficult question. And that's what I am, including me a lot of neurointensivists, they are very interested in this topic. I think really, as I alluded before, only detection is really important, but it's really tough because either patients, they cannot get MRI. There's no way to know who's going to have stroke or not.   Dr. Sung-Min Cho: We know that a bacteremia is a huge risk factor for these patients. Whenever they have device infection, dry valve infection, bacteremia, their stroke risk goes up quite a bit. We have a lot of data on that. So we can carefully monitor these patients, follow these patients. There is some data that, within six days from infection, their stroke risk goes quite high up for these patients. Dr. Sung-Min Cho: But really, neuro-monitoring and biomarker study, there's so little data on this, but patients who are sick like this, not just LVAD patients but ECMO patients or ICU patients, are close neurologic monitoring and some markers to predict occurrence of a stroke or vascular event. I think that's something we really need to study and look into. Dr. Sung-Min Cho: Of course, we have a lot of biomarkers we can pick up from the brain, brain injury markers that we can study, and that has not been done in this space. And there are a lot of opportunities, I think, to look at that. And there's some signal based on Cleveland Clinic data that Randall Starling actually looked into, use of PDE5 inhibitor in this patient population, some protection against the ischemic stroke, and I think that's something also we should look into for neuroprotective agent. Dr. Mercedes Carnethon: Thank you so much! This has been such a delightful discussion this morning with Sung-Min Cho, the lead author of the study and the Associate Editor, Marc Ruel who handled it. Dr. Mercedes Carnethon: I really appreciate your attention. I hope the listeners enjoyed this episode of Circulation on the Run. Please join us again next time. Dr. Greg Hundley: This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit ahajournals.org.  

Host, Stephen Wood and Dr Anne Pringle, a mycologist and botanist, tell the story of the Amanita Phalloides mushroom. This is not a mushroom native to the United States, but it has found its way there in an unsuspecting way, cork trees. These cork trees were imported for use by California wineries but they had a stowaway, the Amanita Phalloides or death cap mushroom. Death caps are toxic mushrooms that kill both humans as well as domestic pets when consumed. These toxic mushrooms resemble several edible species (most notably Caesar's mushroom and the straw mushroom) commonly consumed by humans, increasing the risk of accidental poisoning. Amatoxins, the class of toxins found in these mushrooms, are thermostable: and thus they resist changes due to heat, which means their toxic effects are not reduced by cooking. Signs and symptoms start with an initially self-limiting gastrointestinal illness, that later can result in liver and renal failure and death. The conversation led to a discussion on how to safely collect mushrooms as well as resources to help medical providers and gatherers alike to identify mushrooms. Just as important was a discussion on how we as healthcare providers and environmentalists can prevent invasive species infestations through local action. Mushroom Observer:  https://mushroomobserver.org/ iNat:  https://www.inaturalist.org/ Mushroom Expert:  https://www.mushroomexpert.com/ Guest Bio: Anne Pringle was born in Kuala Lumpur, Malaysia, and spent her childhood travelling through Southeast Asia and West Africa. After being dragged along on one too many birding expeditions, she abandoned the birds for fungi. She was an undergraduate at the University of Chicago, and then completed a PhD in Botany and Genetics at Duke University. After completing a Miller Institute for Basic Research in Science Fellowship at the University of California, Berkeley, she joined the faculty at Harvard University. She next moved to the University of Wisconsin, Madison, where she is now Vilas Distinguished Achievement Professor in the Departments of Botany and Bacteriology. Anne has given over 100 invited talks to academic and popular audiences in countries including China, Colombia, France, Singapore, Sweden, Thailand, and the United States. She has been awarded the Alexopoulos Prize for a Distinguished Early Career Mycologist (2010), the Mendelsohn Excellence in Mentoring Award from the Harvard University Graduate Student Council (2011), the Fannie Cox Prize for Excellence in Science Teaching from Harvard University (2013), and a Radcliffe Institute for Advanced Study Fellowship (2011-2012). Her research has been featured by the New York Times, National Public Radio, Slate, and the Wisconsin State Journal, among others. In 2019, Anne was elected President of the Mycological Society of America.

A look at the weekend where the Widmer crew tried the basic Starbucks drinks for you. A review of pumpkin spice vs apple crisp machiato.

Jeri Bowers is the Director of Development & Public Affairs for MDI Biological Laboratory. Jeri has been a longtime supporter of the Maine Science Festival, and has been instrumental in helping ensure that the MSF features some of the great work happening at MDI Bio Lab.~~~~~~~The Maine Science Podcast is a production of the Maine Science Festival. It was recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. Edited and produced by Kate Dickerson; production support by Maranda Bouchard and social media support from Next Media. The Discover Maine theme was composed and performed by Nick Parker. Support provided by Maine Technology Institute. If you want to support the Maine Science Podcast and/or the Maine Science Festival, you can do so at our website mainesciencefestival.org either at our donation page OR by getting some MSF merchandise through our online store.  Find us online:Website - Maine Science FestivalMaine Science Festival on social media: Facebook    Twitter     InstagramMaine Science Podcast on social media: Facebook    Twitter     InstagramMaine Science Festival Store - https://bit.ly/MSF-storecontact us: podcast@mainesciencefestival.org© 2021 Maine Science Festival

Check out our Sponsors Butcher Box: Get ready for BBQ season with FREE grass-fed beef and free-range organic chicken. Sign up today at butcherbox.com/impact and get 2 NY strip steaks, 6 burgers, and 5 lbs of drumsticks for FREE in your first box. Taft: Visit taftclothing.com and use code IT10 for 10% off your order of any full priced boot, shoe, or sneaker purchase. ShipStation: Get 2 months FREE at ShipStation.com Click on the microphone at the top of the page and type in IMPACT Checkout.com: Learn more at Checkout.com/impact We live in a universe filled with awe and wonderment so much so that scientists of all disciplines have been exploring the world around us for hundreds of years. Although we have made great advances there is still an immeasurable gap in what there is left to discover. Alex Filippenko joins we today to share his vast knowledge as an astrophysicist that has been exploring fundamental physics, black holes, galaxies and more for over 40 years. He breaks down quantum entanglement and the expanding universe and a way that is digestible for nearly everyone.   SHOW NOTES: Star-stuff | Alex shares what people should understand about coming from “star-stuff” [3:07] Contribution & Purpose  | Alex on meaning and contributing to understanding the universe [5:54] Theory | What a good model of theory is and why an ultimate theory may never exist [12:46] Spinoza’s God | Alex speculates what Einstein meant by God in relation to theory [15:31] Expanding Universe | Alex demonstrates what it is to simplify the 4th dimension visually [18:57] Gravity | Why gravity is the weakest of all forces & how it may explain multiple universes [27:46] Black Holes | Speculation of being ripped apart on squeezed singularity and possibilities [31:53] Negative Mass | Making sense of mathematical solutions that appear to be unphysical [42:29] Open Minded | Alex shares why staying open minded is essential and avoiding the trap [50:35] Spooky Action | Alex breaks down quantum entanglement that Einstein called spook action at a distance [55:35] Richard Fineman | Alex shares Fineman’s intuitive view of nature & theory [1:01:04] Always Learning | Alex on educational opportunity and learning as much as possible [1:05:16] Quantum Entanglement | Information traveling faster than the speed of light [1:08:28] Novel Insights | Tom & Alex discuss areas of overlap that creates novel insights [1:16:56] Quality of Life | Alex on quality of time and what you do with your time not stagnate [1:23:18] Into The Future | Alex on the future of humanity, space exploration, life on Mars [1:26:12] Life On Mars | Considering life on Mars and human nature for exploration [1:30:22] Inhabiting Other Planets | Alex on how we could use robots to get humans farther out [1:38:33] Immortality | The possibility of immortality recreating consciousness with computers [1:45:29] Solar Eclipse | Alex warns of the next total solar eclipse coming April 8, 2024 [1:50:39] Aliens |  [1:54:47]   QUOTES: “In a sense, we are the way in which the universe has found to know itself.” [5:30]   “Work hard at maintaining an open mind so you don't get fossilized, so you don't get set in your ways.” [51:59] “If you ever feel comfortable with quantum physics, it probably means you haven't thought about it sufficiently” [1:00:21] “But one of the great things about homosapiens is that we embrace technical challenges. We go for it, we climb the mountain because it's there, first because it's interesting, but secondly, because it ends up having unanticipated spin offs.” [1:14:26]   “to have novel insights, I've just got to take in data that I can't yet predict how it's going to be useful.” Tom Bilyeu [1:17:33] “as physicists, as scientists, initially, we come across these new ideas, quantum entanglement, and you have to just struggle with them and work hard on them and approach them from different perspectives. It's not going to be easy, but good things are hard to do and hard things are good to do.” [1:19:26] “it's the quality of the time that you live. That's actually more important than the duration” [1:23:29]   “You can't just say there are a lot of stars out there, and surely they're teaming with life. There are a lot of factors that lead to life, and then intelligence and mechanical ability at our level. And I think they're fairly rare. I don't think we're unique, but I think they're pretty rare.” [1:56:11]   Follow Alex Filippenko: Website: https://astro.berkeley.edu/people/alex-filippenko/ LinkedIn: https://www.linkedin.com/in/alex-filippenko-a35520a1/ Facebook: https://www.facebook.com/alex.filippenko Instagram: https://www.instagram.com/filippenkoalex/   Guest Bio: Alex Filippenko is a Richard & Rhoda Goldman Distinguished Professor in the Physical Sciences, and a Miller Senior Fellow in the Miller Institute for Basic Research in Science (UC Berkeley). His accomplishments, documented in about 960 research papers, have been recognized by several major prizes, including a share of both the Gruber Cosmology Prize (2007) [...] In 2017, he was selected for the Caltech Distinguished Alumni Award. He has won the most prestigious teaching awards at UC Berkeley and has also been voted the “Best Professor” on campus a record 9 times… SOURCE: https://astro.berkeley.edu/people/alex-filippenko/      

Melanoma is much less common than some other types of skin cancers, but it is more dangerous because it’s much more likely to spread to other parts of the body if not caught and treated early. While there have been some exciting advances in melanoma research in recent years, there is much left to learn about, for example, how it spreads, how it resists treatment, and therapies could be improved. In this episode, three scientists at the Sidney Kimmel Cancer Center who are investigating different aspects of melanoma explain why it’s a challenging disease, describe recent advances against it, and underscore why there are so many reasons to be excited. 4:11 - Andrew Aplin, PhD, is Associate Director of Basic Research at the Sidney Kimmel Cancer Center and Professor in the Department of Cancer Biology. Chris Snyder, PhD, is Associate Professor in the Department of Microbiology and Immunology at the Sidney Kimmel Cancer Center. Neda Nikbakht, MD, PhD, is Assistant Professor in the Department of Dermatology and Cutaneous Biology at the Sidney Kimmel Cancer Center. 4:42 – Dr. Aplin on his research into why melanoma is so resistant to therapy 5:59 – Dr. Snyder on his work into why the immune system sometimes doesn’t seem to recognize cancer 8:11 – Dr. Nikbakht, a dermatologist who sees patients with skin cancer, discusses how she studies the skin microbiome to learn what properties promote melanoma 10:43 – The tremendous recent advances in melanoma treatment 13:59 – What we’ve learned about the immune system in recent years 18:02 – A physician’s perspective on recent advances in melanoma research 22:04 – The big picture goal of Dr. Aplin’s research 26:51 – Dr. Snyder’s move into cancer immunology 32:00 – Dr. Nikbakht on the tremendous importance of patient samples in research 37:46 – How the collaborative environment at the Sidney Kimmel Cancer Center enhances their research 43:26 – The impact of ACS funding on their work 47:16 – Why advances made during the push to develop COVID-19 vaccines could be very impactful for cancer research 49:01 – A message they’d like to share with cancer patients, survivors, and caregivers

The rapid accumulation of ice creates significant challenges for U.S. military operations and civilian activities in cold environments. It hampers mobility, disrupts communication, creates power outages and degrades infrastructure.That's why a team of ERDC researchers is conducting innovative basic research to unravel the physical processes of how ice attaches to different surfaces, paving the way for the future development of advanced protective coating materials and the expansion of existing treatments to broader applications.On this episode of the Power of ERDC podcast, we are joined by Dr. Emily Asenath-Smith, a research materials engineer at ERDC's Cold Regions Research and Engineering Laboratory (CRREL) in Hanover, New Hampshire.We discuss why CRREL is the perfect place to conduct this research (3:04), the importance of studying ice adhesion (3:51), basic research and why it matters (4:32), how this research will help the military (11:07), the unique method used by the research team to grow ice (19:08) and long-term practical applications (17:10).Visit https://www.PowerofERDCPodcast.org for more information.

Jonathan Lang speaks with David A. Largaespada, PhD, who is a full professor in the Departments of Pediatrics and Genetics, Cell Biology, and Development and the Associate Director for Basic Research in the Masonic Cancer Center at the University of Minnesota. See omnystudio.com/listener for privacy information.

Shooting Spores: Understand the Physics of the Most Amazing Apparatuses on Earth Presented by Anne Pringle, PhD Fungi use spores to move between habitats and spore dispersal is critical to their success. Fungi use an astonishing array of apparatuses and strategies to move their progeny: sacs filled with fluid that explode like water balloons, collapsing drops of liquid, and winds created by the cooperative release of hundreds of thousands of their spores. Fungi may even sense impending thunderstorms and use their updrafts to disperse longer distances. I’ll talk about all of this amazing biology and try and convince you that fungi actively manipulate the fates of their spores, a contrast to the perception of spore release as entirely passive. Anne Pringle was born in Kuala Lumpur, Malaysia, and spent her childhood traveling through Southeast Asia and West Africa. After being dragged along on one-too-many birding expeditions, she abandoned the birds for fungi. She was an undergraduate at the University of Chicago, and then completed a Ph.D. in Botany and Genetics at Duke University. After completing a Miller Institute for Basic Research in Science Fellowship at the University of California, Berkeley, she joined the faculty at Harvard University. She next moved to the University of Wisconsin, Madison, where she is now Vilas Distinguished Achievement Professor in the Departments of Botany and Bacteriology. She has been awarded the Alexopoulos Prize for a Distinguished Early Career Mycologist (2010), the Mendelsohn Excellence in Mentoring Award from the Harvard University Graduate Student Council (2011), the Fannie Cox Prize for Excellence in Science Teaching from Harvard University (2013), and a Radcliffe Institute for Advanced Study Fellowship (2011-2012). IllinoisMyco.org Recorded via Zoom on April 5, 2021

Ronnie Fass MD is a Professor of Medicine at Case Western Reserve University. He is the Director of the Division of Gastroenterology and Hepatology, and Heads the Esophageal and Swallowing Center at MetroHealth Medical Center in Cleveland. Dr. Fass earned his medical degree from Ben-Gurion University Faculty of Medicine in Israel. He then moved to the United States and pursued a residency in Internal medicine at the University of Arizona Medical Center before completing his fellowship in Gastroenterology from UCLA Medical Center. Dr. Fass serves as the editor-in-chief of the Journal of Clinical Gastroenterology and The Journal of Neurogastroenterology and Motility. Dr. Fass has published more than 550 articles, editorials, commentaries, and abstracts in reputed journals. He is the recipient of various awards and honors including the American Gastroenterological Association/Janssen Award for Digestive Sciences in Clinical or Basic Research. When did you decide to study medicine? What about a specialty? These are big decisions which are likely to affect the rest of your life. How do you make the right decision? Today, Dr. Ronnie Fass shares the secret to his approach on making these decisions. He tells us that he made sure to lay the groundwork, he did his research, but most importantly he talked to people who had already taken the journey he was considering, and his mentors. So how did it turn out? Dr. Fass asserts, “Even now, 30, 40 years down the line, I still feel this was the proper path for me.” Pearls of Wisdom: 1. When you need to make an important decision, lay the groundwork: talk to people who know you and understand the subject that you're making a decision about, and consult with expert mentors. 2. When you reach out to mentors, show enthusiasm and seriousness. It's not just that a mentor feeds you and you eat. You have to have the ingredients and listen to them about how to prepare an amazing meal. 3. Listen to patients and give them time. Read their charts beforehand so that you have a background. Never skip the physical examination, which is critical to your role as a healer. Follow up in a timely manner and keep communication open.

Featuring: Christina L. Goldstein, MD, FRCSC, Scott D. Daffner, MD, Gregory D. Schroeder, MD Disclosures: Daffner, Scott D.: Consulting: Bioventus (B); Fellowship Support: AO Spine (E, Paid directly to institution/employer), Medtronic (D, Outside 12-Month Requirement, Paid directly to institution/employer); Grants: AO Foundation (F, Outside 12-Month Requirement, Paid directly to institution/employer), CSRS (F, Outside 12-Month Requirement, Paid directly to institution/employer); Other Office: CSRS (Research Committee), LSRS (Program Committee), NASS (Section on Biologics & Basic Research), NASS (Membership Committee); Research Support (Staff and/or materials): Bioventus (C, Paid directly to institution/employer), Pfizer (D, Paid directly to institution/employer), Spinal Kinetics (B, Paid directly to institution/employer); Stock Ownership (including options, warrants): Amgen (

Most sophisticated cyber attack follow the well-known cyber kill chain. The first step of the cyber kill chain is the reconnaissance phase where attacker probe the network in search of weakness, misconfiguration, vulnerabilities, and identify potential targets before the actual attack start. To this end, the attacker need to collect important information about the characteristics of each devices (i.e., hardware, operating system, applications), the network topology, the different subnet, firewall rules, access control, privilege, the communication protocol at each layer, and the machine learning algorithm on each IoBT devices. The attacker reconnaissance can be summarized by an attack graph in which the node represent vulnerable IoBT devices and the edge show their associated vulnerabilities. This work investigates cyber deception as a complex game in which each player has three concurrent and interdependent objectives. Each players imperfectly monitor (partial observation) other players' action to find out each player's identity, strategies, payoff, available information, capability, and to continuously predict their intent. Each player strategically select to which players to hide particular information (e.g., camouflage). Each player judiciously manipulate other players' perception (e.g., decoy) based on his observed action, estimated capability, and predicted intent. This work examines from the defender's perspective several deception game on an attack graph. The defender goal is to stop the attacker early in the cyber kill chain and prevents the subsequent more dangerous phases. About the speaker: Charles A. Kamhoua is a researcher at the Network Security Branch of the U.S. Army Research Laboratory (ARL) in Adelphi, MD, where he is responsible for conducting and directing basic research in the area of game theory applied to cyber security. Prior to joining the Army Research Laboratory, he was a researcher at the U.S. Air Force Research Laboratory (AFRL), Rome, New York for 6 years and an educator in different academic institutions for more than 10 years. He has held visiting research positions at the University of Oxford and Harvard University. He has co-authored more than 150 peer-reviewed journal and conference papers. He is a co-inventor of 2 patents and 5 patent applications. He has been at the forefront of several new technologies, co-editing three books at Wiley-IEEE Press entitled "Assured Cloud Computing", "Blockchain for Distributed System Security" and "Modeling and Design of Secure Internet of Things", forthcoming. He has presented over 50 invited keynote and distinguished speeches and has co-organized over 10 conferences and workshops. He has mentored more than 60 young scholars, including students, postdocs, and Summer Faculty Fellow. He has been recognized for his scholarship and leadership with numerous prestigious awards, including the 2019 Federal 100-FCW annual awards for individuals that have had an exceptional impact on federal IT, the 2018 ARL Achievement Award for leadership and outstanding contribution to the ARL Cyber Camo (cyber deception) project, the 2018 Fulbright Senior Specialist Fellowship, the 2017 AFRL Information Directorate Basic Research Award "For Outstanding Achievements in Basic Research," the 2017 Fred I. Diamond Award for the best paper published at AFRL's Information Directorate, 40 Air Force Notable Achievement Awards, the 2016 FIU Charles E. Perry Young Alumni Visionary Award, the 2015 Black Engineer of the Year Award (BEYA), the 2015 NSBE Golden Torch Award—Pioneer of the Year, and selection to the 2015 Heidelberg Laureate Forum, to name a few. He has been congratulated by the White House, the US Congress and the Pentagon for those achievements. He received a B.S. in electronics from the University of Douala (ENSET), Cameroon, in 1999, an M.S. in Telecommunication and Networking from Florida International University (FIU) in 2008, and a Ph.D. in Electrical Engineering from FIU in 2011. He is currently an advisor for the National Research Council postdoc program, a member of the FIU alumni association and ACM, and a senior member of IEEE.

Chris Steyn, MD (McMaster University) and Christina Goldstein MD, FRCSC (University of Missouri) discuss quality of life for patients with metastatic disease of the spine. Disclosures: Steyn, Chris : Nothing to Disclose Goldstein, Christina L.: Consulting: SpineSource (B); Speaking and/or Teaching Arrangements: AOSpine North America (B); Trips/Travel: AOSpine North America (B, Paid directly to institution/employer), DePuy Synthes Spine (A); Other Office: North American Spine Society (Nonfinancial, Coverage Committee, Section on Biologics and Basic Research); Grants: University of Missouri Coulter Translational Partnership (C, Paid directly to institution/employer), Musculoskeletal Transplant Foundation (E). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

At the “Innovation: An American Imperative” symposium October 20 on Capitol Hill, industry leaders and members of Congress talked about shoring up federal support for basic research and development  

At the “Innovation: An American Imperative” symposium October 20 on Capitol Hill, industry leaders and members of Congress talked about shoring up federal support for basic research and development